How is it different from older Fabry enzyme therapies?

It is PEGylated and chemically cross-linked, which increases enzyme stability and prolongs its half-life relative to agalsidase alfa and agalsidase beta.

How strong is the evidence behind it?

It has human phase 3 data, including the randomized head-to-head BALANCE trial against agalsidase beta and the open-label BRIDGE and BRIGHT switch studies.

What are the main safety concerns?

Infusion-associated and hypersensitivity reactions are the most notable, and some patients develop anti-drug antibodies, so it is given under specialist supervision.

Is this something a person can obtain or dose on their own?

No. It is a hospital- or clinic-administered intravenous biologic prescribed and monitored by physicians experienced in Fabry disease.

EMA-approvedaka Elfabrio

Pegunigalsidase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Pegunigalsidase alfa (also known as Elfabrio) is a peptide catalogued under Enzymes (Fabry (PEG)). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Pegunigalsidase alfa?

Pegunigalsidase alfa (brand name Elfabrio) is a PEGylated, chemically cross-linked recombinant human alpha-galactosidase A used as enzyme replacement therapy (ERT) for adults with confirmed Fabry disease. It received FDA and EMA marketing authorization in 2023. It is a prescription-only biologic administered by intravenous infusion under medical supervision, not a research chemical or supplement.

The evidence base is human and relatively strong for a rare disease: a randomized, active-controlled phase 3 head-to-head trial (BALANCE) plus two open-label phase 3 switch studies (BRIDGE and BRIGHT).

How does Pegunigalsidase alfa work?

Pegunigalsidase alfa supplies a functional copy of alpha-galactosidase A, the lysosomal enzyme deficient in Fabry disease, so that accumulated globotriaosylceramide (Gb3/GL-3) can be hydrolyzed and cleared.

Chemical cross-linking and PEGylation increase the enzyme's molecular stability and prolong its circulating half-life compared with earlier ERTs.

What does the research say about Pegunigalsidase alfa?

In the 2-year phase 3 BALANCE trial, pegunigalsidase alfa was non-inferior to agalsidase beta for the rate of eGFR decline in Fabry patients with deteriorating renal function. ^[1]
Its PEGylation and cross-linking give a substantially longer plasma half-life than earlier recombinant alpha-galactosidase A products. ^[4]
An every-4-weeks infusion schedule maintained disease stability in adults switched from other enzyme replacement therapies in the phase 3 BRIGHT program. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study — Wallace EL et al., Journal of Medical Genetics 2024. (Randomized controlled phase III trial)
[2] Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study — Linhart A et al., Orphanet Journal of Rare Diseases 2023. (Open-label phase 3 switch study)
[3] A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies — Holida M et al., Journal of Inherited Metabolic Disease 2025. (Open-label phase III trial (BRIGHT))
[4] Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease — Germain DP et al., Frontiers in Genetics 2024. (Narrative review)
[5] Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review — Jovanovic A et al., Journal of Clinical Medicine 2025. (Systematic literature review)
[6] Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials — Azimpour K et al., Advances in Therapy 2025. (Trial-based quality-of-life analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In its approved label the drug is given as an intravenous infusion (typically 1 mg/kg every 2 weeks), while an every-4-weeks regimen was evaluated in the BRIGHT studies.

Dosing, premedication, and infusion monitoring are determined and supervised by the treating clinician; no self-administration figures are provided here.

Side effects & safety profile

The most common risks are infusion-associated and hypersensitivity reactions, which can include serious events; premedication and slowed infusion rates are used to manage them.

Anti-drug (neutralizing) antibodies can develop, and immunogenicity was a specific analysis endpoint in the BALANCE study.

Because Fabry disease and this ERT require specialist management, it must only be used under a physician experienced in inherited metabolic disease; this page is educational and not a substitute for medical care.

Stacking & combinations

This is a single-agent prescription enzyme replacement therapy and is not intended to be combined or stacked with other peptides or performance compounds.

Finding Pegunigalsidase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved by the FDA and EMA (2023, brand Elfabrio) as enzyme replacement therapy for adults with confirmed Fabry disease.

References

[1] Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study — Wallace EL et al., Journal of Medical Genetics 2024. PMID: 37940383. View sourceStudy: Randomized controlled phase III trialPegunigalsidase alfa was non-inferior to agalsidase beta for annualized eGFR decline over 2 years.
[2] Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study — Linhart A et al., Orphanet Journal of Rare Diseases 2023. PMID: 37865771. View sourceStudy: Open-label phase 3 switch studyPatients switched from agalsidase alfa maintained or improved renal and disease parameters on pegunigalsidase alfa.
[3] A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies — Holida M et al., Journal of Inherited Metabolic Disease 2025. PMID: 39381863. View sourceStudy: Open-label phase III trial (BRIGHT)An every-4-weeks schedule kept disease stable in adults previously on other ERTs.
[4] Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease — Germain DP et al., Frontiers in Genetics 2024. PMID: 38680424. View sourceStudy: Narrative reviewReviews the molecular design, PEGylation, half-life, and clinical development of pegunigalsidase alfa.
[5] Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review — Jovanovic A et al., Journal of Clinical Medicine 2025. PMID: 40725823. View sourceStudy: Systematic literature reviewSynthesizes comparative efficacy and effectiveness data across Fabry disease therapies including pegunigalsidase alfa.
[6] Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials — Azimpour K et al., Advances in Therapy 2025. PMID: 39847314. View sourceStudy: Trial-based quality-of-life analysisDerived health-state utility values from the pegunigalsidase alfa clinical trial program.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.